In patients with chronic myelogenous leukemia ( CML ), abnormal expansion of myeloid cells is maintained by expression of the p210 bcr -abl fusion protein. Thus, this protein and its mRNA represent primary targets to inhibit proliferation of these cells. Here we describe the properties of a ribozyme against the bcr -abl mRNA, expressed as a fusion transcript with the human U1 small nuclear RNA or the adenovirus VA1 RNA and delivered to the cells through retroviral vectors. These fusion ribozymes are specifically localized in the nucleus or in the cytoplasm, respectively. Transduction of 32D -LG7 myeloid cells, whose growth is IL -3 independent thanks to deregulated bcr -abl expression, imposed strong negative selective pressure on cell growth and induced restoration of an IL -3 -dependent phenotype. Although expressed at a level similar to that of the U1 -fusion ribozyme, the cytoplasmic VA1 ribozyme was a more powerful inhibitor of p210 bcr -abl gene expression. In cells transduced with the vector expressing this ribozyme, the levels of the bcr -abl transcript were reduced up to 10 4 -fold, the p210 bcr -abl protein became undetectable, and the cells underwent massive apoptosis when cultured in the absence of IL -3. Transduction of primary hematopoietic cells obtained from bone marrow of patients with CML resulted in remarkable reduction of bcr -abl mRNA levels, starting a few days after transduction. These results show the feasibility and efficacy of vector -expressed anti -bcr -abl ribozymes for purging of CML cells.
C hronic myelogenous leukemia ( CML ) is a proliferative disorder of the myeloid compartment resulting from the clonal expansion of cells with defined genetic abnormalities. Enhanced cellular proliferation is associated with the presence of a characteristic reciprocal translocation between the long arm of chromosome 9 and the long arm of chromosome 22 [t( 9; 22 )( q34:q11) ]. This genetic rearrangement determines the transposition of the c-abl gene on chromosome 9 within the bcr gene on chromosome 22, resulting in the creation of an abnormal gene that occurs by fusion of either bcr exon 3 to c -abl exon 2 ( splice 1 ) or bcr exon 2 to c -abl exon 2 ( splice 2).
1,2 The mRNA transcript from this fusion gene and its translation product, p210
bcr -abl , are found in virtually all patients with CML, even those in whom no gross cytogenetic abnormality is evident. 3 Currently, the only curative therapy for CML is allogeneic bone marrow transplantation. 4 Unfortunately, a large proportion of patients with CML may not be eligible for allogeneic transplantation because of either advanced age or lack of a suitable donor. Among the possible alternative therapies, autologous transplantation has long been proposed, 5 based on the observation that a suppressed but functionally intact reservoir of normal stem cells persist in patients with CML during the chronic phase of the disease. 6 -8 The clinical experience with autologous transplantation studies indicates that autografting with unpurged autologous marrow or blood may extend survival for patients with CML. 9 However, relapse is a common event because leukemia progenitor cells remain in the infused marrow to contribute to systemic relapse. 10 To selectively impair the growth of Ph + cells in bone marrow transplants, several in vitro purging procedures have been suggested in the last few years. These entailed treatment with cyclophosphamide derivatives, 11, 12 IFN -, 9 or ex vivo expansion in long -term liquid culture conditions. 13 Following these procedures, however, cytogenetic remissions are of relatively short duration, whereas in several cases, the proposed ex vivo manipulations may damage or deplete the stem cells. 9 Treatment of bone marrow transplants with antisense oligonucleotides targeting bcr-abl has also been proposed for pretransplantation bone marrow purging. 14 Although this procedure is effective in transiently inhibiting expression of the bcr-abl gene product in experimental models, major concerns on their efficiency are raised by the relative inefficiency of delivery of these molecules, 15 by their relatively unspecific and uncontrolled effects on other mRNAs, 16 by the limited period of time when their function is exerted, 9 and by the fact that not all malignant hematopoietic progenitors may express the bcr-abl mRNA at the time of treatment. 17 A more attractive possibility is to target the bcr-abl mRNA using ribozymes, a class of RNA molecules that can cleave other RNA sequences enzymatically. Whereas several studies performed in the last years have indicated that this approach is feasible, 18 -21 still several issues must be addressed to improve its effectiveness. In particular, strategies have to be devised to obtain high -level expression of ribozymes inside the cells and to target these molecules to the same cellular compartment as the target mRNA substrate. 22, 23 Both these requirements can be fulfilled by embedding the ribozymes in the context of exogenous RNA molecules that also provide stability and appropriate conformation for catalytic activity, and by delivery of these constructs using viral vectors.
Here we compare the efficiency of two retroviral vectors expressing an anti-bcr3 /abl2 ribozyme expressed as fusions to the human U1 snRNA or the adenovirus VA1 RNA genes to obtain high -level expression and specific intracellular compartmentalization.
Methods

U1 -and VA1 -fusion ribozymes
The sequence and the in vitro biochemical properties of the hammerhead ribozyme cleaving the bcr3 /abl2 mRNAshown in Figure 1A -have been already described by Snyder et al. 24 A double -stranded DNA fragment encoding the ribozyme ( RibB3A2) was obtained by annealing the complementary 3-2 RIBO and 3 -2 A RIBO synthetic deoxyoligonucleotides ( Table 1 ) , containing BamHI -compatible sites at their 5 0 extremities. The mutated B3A2m ribozyme contains a single point mutation in the catalytic site, which abolishes enzymatic activity. 25 This mutated ribozyme was obtained with a strategy similar to the wild type using oligos 3 -2 RIBOm and 3 -2 A RIBOm ( Table 1 ) .
The U1 snRNA gene was obtained by PCR amplification from human genomic DNA using primers U1SX and U1DX ( Table 1 ) , containing EcoRI and BamHI restriction sites at their 5 0 ends, respectively, and cloning into the respective sites of the pBluescript II vector ( Stratagene, La Jolla, CA ).
To allow cloning of the RibB3A2 ( BamHI /BamHI extremities ) ribozyme into U1 gene, an internal BamHI site was introduced (Fig 1B ) by recombinant PCR using primer pairs U1SX / U1 -Bam and U1 -Bcl /U1DX (Table 1 ) . Finally, plasmids (pBS /U1 -RibB3A2, pBS /VA1 -RibB3A2, and pBS /VA1 -RibB3A2m ) encoding either U1 or wild type and mutated VA1 ribozymes were constructed by cloning the RibB3A2 fragment (BamHI / BamHI extremities ) into pBS -U1 /BamHI and pBS -VA1 -BglII 26 vectors, respectively. The latter vector was a kind gift of Irene Bozzoni.
Transfections
The pBS /U1 -RibB3A2 or pBS /VA1 -RibB3A2 plasmids were cotransfected with pSV2neo (Stratagene ) into human epithelial 293 cells by lipofectin ( Gibco BRL, Rockville, MD ), according to manufacturer's procedure. After transfection, cells were grown for additional 48 hours before selection. After 10 days of selection, stable transfected cells were obtained and analyzed by Northern blot and fluorescent in situ hybridization ( FISH ).
Retroviral vectors and transductions
The N2A /U1 -RibB3A2, N2A /VA1 -RibB3A2, and N2A / VA1 -RibB3A2m retroviral plasmids were constructed by cloning the U1 -RibB3A2 (EcoRV / SacII ), VA1 -RibB3A2 ( HincII / SacII ) and VA1 -RibB3A2m ( HincII /SacII ) transcriptional units into the 3 0 LTR region of the N2A doublecopy vector 27 using the SnaBI and SacII sites. The N2A vector expressing the VA1 cassette alone was obtained by excising the VA1 cassette from pBS -VA1 -BglII using HincII and SacII and cloning this fragment into N2A using SnaBI and SacII.
Transducing retroviral vectors were obtained by two consecutive packaging passages into ecotropic Psi2 and amphotropic PA317 murine packaging cells. Transduced PA317 cells were selected with 0.6 g/ml G418. After 2 weeks, individual clones were harvested, expanded, and screened for high -titer virus producers. Viral titers were determined by a competitive PCR assay on NIH3T3 cells as already described. 28 Clones producing $1Â10 6 provirusforming units/ml were used for the transduction experiments.
Transduction was performed by the addition of 2 ml of prefiltered retrovirus-containing supernatant (MOI= 2 ) to 1Â10 6 32D -LG7 cells, 29 a kind gift of M. A. Santucci, in the presence of 16 g /ml protamine. Three cycles of infection of 4 hours each were performed followed by a final step of Figure 1 Fusion ribozymes against bcr -abl mRNA. A: Schematic representation of the anti -bcr -abl hammerhead ribozyme used in this work, with the indication of the complementary sequences on the B3A2 bcr -abl fusion region. The ribozyme cleavage site is boxed. In RibB3A2m, the G in position 5 of the ribozyme is substituted with a U. This mutation renders the ribozyme catalytically inactive. 25, 59 B: Schematic representation of the U1 snRNA secondary structure, with the indication of the site of cloning of the RibB3A2 ribozyme. The gray boxed sequence corresponds to the wild -type sequence of human U1 snRNA. The sequence in italics corresponds to a linker DNA inserted for cloning purposes. The bold typed and boxed sequence corresponds to the 5 0 and 3 0 ends of the ribozyme, respectively. C: Cloning of the RibB3A2 ribozyme into the adenovirus 2 VA1 RNA. The ribozyme was excised from the U1 -B3A2 construct of ( B ) using BamHI and cloned in the compatible BglII site of a modified adenovirus VA1 RNA -containing plasmid. 26 The predicted secondary structure of VA1 is shown at the bottom, with the indication of the cloning region. The sequence in gray boxes corresponds to wild -type VA1, the sequence in italics to a linker added for cloning purposes. D: Northern blotting of 293 cells transfected with the fusion ribozymes. The specific RNAs detected by a ribozyme probe are indicated by arrows. E: Northern blotting of 32D -LG7 cells transduced with the retroviral vectors expressing the fusion ribozymes. The specific RNAs ( LTR transcript and fusion ribozymes short RNAs ) detected by a ribozyme probe are indicated by arrows.
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Targeted anti-bcr-abl ribozymes Mendoza -Maldonado et al 12 hours. After the end of the transduction procedure, cells were maintained for additional 24 hours before analysis.
During the whole period, cells were maintained in the presence of 5 U / ml murine IL -3 (Gibco BRL ). 
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Mononuclear cells (1Â10 6 ) from bone marrow were obtained from three patients with bcr-abl mRNA -positive chronic phase CML with the B3A2 translocation by Ficoll density gradient centrifugation and cultured in IMDM with 20% FCS, 100 mM 2-mercaptoethanol, 10 g/ml IL -3, 10 g/ml GM -CSF and 10 g /ml SCF. After 48 hours, the medium was replaced with 1 ml of prefiltered retroviruscontaining supernatant, 16 g /ml protamine, 10 g /ml each of IL -3, GM -CSF, and SCF. Transduction was performed using two cycles of infection of 6 hours each followed by a final step of 12 hours. After the end of the transduction procedure, cells were maintained in supplemented IMDM. After 2 and 5 days, cells were harvested and examined for the presence of bcr-abl transcripts by competitive RT-PCR analysis.
Northern blotting
Total RNA was extracted from transduced cells using the Chomczynski and Sacchi procedure. 30 Ten micrograms of RNA was subjected to electrophoresis on 3% NuSieve agarose /formaldehyde gels and transferred to nylon (Nytran ) membranes using a downward capillary transfer system ( Turboblotter; Scheicher & Schueller, Daseel, Germany ). Blots were fixed by UV cross -linker (Stratalinker; Stratagene ) and hybridized overnight with either 32 P -labeled -actin 28 or 3 -2 A RIBO probes ( see Table 1 ) at 578C in Church solution. 31 After a final wash in 0.1Â SSC / 0.1% sodium dodecyl sulfate (SDS ) for 15 minutes at 658C, membranes were exposed to X -ray films.
Fluorescent in situ hybridization ( FISH )
Cells were grown on a chamber slide ( Nalge Nunc International, Naperville, IL ) for 48 hours and analyzed using the procedure described by Raap et al with slight modifications. 32 Cells were fixed for 30 minutes in 4% paraformaldehyde /5% acetic acid /PBS, permeabilized at 378C in 2 g/ml proteinase K, and postfixed in 1% paraformaldehyde. Prehybridization was performed at 428C for 1 hour in 1:1 4Â SSC:formamide containing 100 g/ ml of salmon sperm DNA. Hybridization was performed with digoxigenin (DIG )-labeled RibB3A2 RNA probe transcribed using DIG RNA labeling kit ( Boehringer Mannheim, Mannheim, Germany ) at 428C overnight. After washing in 2Â SSC, 1Â SSC, and 0.5Â SSC, cells were incubated with anti -DIG -fluorescein (Boehringer Mannheim ) antibody for 45 minutes. After washing, cells were visualized by fluorescence microscopy.
Analysis of apoptosis
The presence of apoptotic cells was quantitatively analyzed by cytofluorometric analysis on a FACSCalibur (Becton Dickinson Immunocytometry Systems, San Jose, CA ) using the Annexin -V-FLUOS procedure (Boehringer Mannheim ) following the procedure described by the manufacturer.
Quantitative competitive PCR
DNA competitors for the quantification of the proviral DNAs containing the U1 -and VA1 -ribozyme cassettes and for the quantification of the murine -globin gene copy number were constructed using the method described by Celi et al to obtain DNA fragments with the same sequence as the target DNAs but 20 nt shorter. 33 These competitors were added in scalar quantities to genomic DNA of transduced cells, extracted as already described. 28 PCR amplification was carried out using primer pairs U1 -R /RIB -R for the U1 construct, LTR -SX /RIB -R for the VA1 construct, and B -GL -E2 / B -GL -IB for the murine -globin gene (see Table 1 for primer sequences and Figure 5 for primer localization ). 
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Competitive PCR for RNA quantification was performed using total RNA extracted from transduced cells according to standard procedures. 30 RNA was treated with DNase I 
Targeted anti-bcr-abl ribozymes Mendoza -Maldonado et al ( Gibco BRL ) and reverse transcribed using 200 U Mo -MLV RT (Gibco BRL ) and 1 M of random hexameric primers ( Gibco BRL ). The competitor for bcr-abl cDNA quantification was obtained by an already described recombinant PCR procedure that generates a DNA fragment with the same sequence as the target cDNA and with the addition of 20 extra bp in the middle. 34, 35 The competitor for murine -actin mRNA quantification was obtained by
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A competitive PCR analysis on transduced CML Ph + cells was performed using a multicompetitor DNA fragment containing primers for amplification of human bcr-abl transcripts, human -actin transcripts, VA1 -ribozyme provirus, human -globin gene ( see Table 1 for primer sequences ). This multicompetitor contains these primer sites arranged to generate PCR products of different but comparable sizes to those obtained from amplification of genomic DNA, and was constructed by a recombinant PCR procedure as already described. 36 
Western blotting
A total of 10 6 cells were lysed in SDS sample buffer. After boiling for 5 minutes, lysates were subjected to electrophoresis on 7% polyacrylamide gels and transferred to nitrocellulose membranes using a semidry transfer system ( BioRad, Richmond CA ). Blots were incubated in 5% milk TBS buffer 37 with 1:500 anti -BCR antibody ( Santa Cruz Biotechnology, Santa Cruz, CA ) at room temperature for 2 hours, washed in TBS supplemented with 0.05% Tween 20 (TBST ), and incubated for 1 hour with a goat anti -mouse horseradish peroxidase -conjugated antibody ( 1:2000 dilution ) (DAKO, Glostrup, Denmark ). Protein bands were visualized using an ECL detection system ( Amersham Pharmacia Biotech, Uppsala, Sweden). Alternatively, detection was performed using an anti -ABL antibody at 1:500 dilution ( Santa Cruz Biotechnology).
Results
Retroviral vectors for targeted intracellular expression of an anti -bcr -abl ribozyme
The nucleotide sequence of the bcr exon 3 /abl exon 2 (b3a2 ) mRNA junction contains a GUU triplet positioned three bases 5 0 of the fusion site, allowing the design of hammerhead ribozymes specifically recognizing and cleaving this transcript. Several ribozymes have been described in the recent literature that exploit this property, differing for flanking arm length and match to the target RNA sequence. 18, 20, 38 All through this work, we have used a hammerhead ribozyme with a flanking stem III arm of 15 nt and a stem I arm of 14 nt, cleaving at position À 3 upstream of the bcr-abl b3a2 fusion site (Fig 1A ) . This RNA molecule is capable of forming a stable duplex with its target mRNA, but not with normal bcr or c-abl sequences as they lack adequate homology to one or the other halves of the ribozyme sequence. Extensive in vitro analysis of substrate specificity, Mg 2 + dependency, and functional activity of this ribozyme has already been reported by Snyder et al. 24 To obtain intracellular expression of this ribozyme as well as its targeting to the relevant cellular compartments, the ribozyme cDNA was cloned either two bases downstream of the 3 0 splicing recognition site of the human U1 snRNA or as a substitute to a portion of the central domain of the adenovirus type 2 VA1 gene, 26 as shown in Figure 1B and C, respectively. In both fusions, the catalytic activity of the ribozyme was retained and no differences were detected in the kinetics or specificity of in vitro cleavage ( not shown ). In the VA1 construct, we also cloned a mutated version of the ribozyme, in which a single point mutation in the catalytic site abolishes enzymatic activity. 25 To verify the levels and pattern of expression of these fusion constructs inside the cells, the U1 -and VA1 -RibB3A2 transcriptional units were cloned into the pBluescript II vector, which was then transfected into human epithelial 293 cells together with the pSV2neo plasmid. Stable clones obtained by selection for G418 resistance were analyzed by Northern blotting using a ribozyme -specific probe. As shown in Figure 1D , both the U1 -and the VA1 -RibB3A2 chimeric RNAs were expressed at high levels in the transduced cells as short transcripts of the expected sizes.
Finally, to attain high efficiency of expression of the U1 -and VA1 -ribozyme cassettes in CML cells, two retroviral vectors were constructed, in which the U1 -and VA1 -RibB3A2 transcriptional units were cloned into the 3 0 LTR of the N2A double -copy vector. 27 Other studies have demonstrated that high steady -state expression levels can be achieved by inserting short RNA pol III or Pol II expression cassettes into the U3 region of the Moloney virus LTR. 39, 40 Recombinant retroviral vectors were obtained by two consecutive packaging passages using the ecotropic Psi2 and the amphotropic PA317 packaging cell lines, and the best producer clones (1Â10 6 provirusforming units /ml ) screened by competitive PCR. 28 The levels and patterns of expression of the two retroviral vectors were assessed by Northern hybridization of RNA C, and D) , or to the transduced cell cDNA for cellular -actin and bcr -abl quantifications ( B and E ), and amplification was carried out with the respective primer pairs. Amplification products were resolved by polyacrylamide gel electrophoresis, stained with ethidium bromide, photographed, and quantified. The position of the competitor ( C ) and target ( T ) bands is indicated by arrows on the right side of each gel. According to the principles of competitive PCR, the ratio between competitor and target ( C / T; shown at the bottom of the gels for the lanes where both species were detectable ) reflects the ratio between the two species at the beginning of the reaction, and is linearly related to the input amount of competitor in the reaction. According to the equation fitting these values, the number of target molecules in the analyzed volume of samples was evaluated and it is reported on the rightmost side of each panel. M: molecular weight marker; Rib: ribozyme.
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Targeted anti-bcr-abl ribozymes Mendoza -Maldonado et al from transduced 32D -LG7 cells -a myeloid cell line expressing high levels of p210 bcr -abl (see below) -at day 5 after transduction, while the cells had been maintained in the presence of IL -3. Contrary to mock -transduced cells, total RNA from 32D -LG7 cells transduced with the two recombinant retroviral vectors expressing the chimeric ribozymes showed specific hybridization to a ribozyme probe ( Fig 1E ) . In each of the transfected cell populations, two transcripts were observable. The longer one had a size compatible with the mRNA originating from the vector LTR and spanning the whole proviral construct, whereas the shorter one was identical in size to the expected short RNA transcribed from the inserted cassette. The levels of expression of both the LTR -driven and the cassette -driven transcripts were comparable, and no gross differences were observed between the efficiency of transcription of the U1 -and the VA1 -RibB3A2 short RNAs.
Altogether, these results confirm that chimeric ribozymes can be expressed intracellularly with high efficiency by fusion to U1 and VA1 RNAs, followed by cloning into double -copy retroviral vectors and cellular transduction.
Cellular compartmentalization of U1 -and VA1 -fusion ribozymes
The U1 -and VA1 -RibB3A2 transcriptional units vary in the nature of the promoter / enhancer sequences used for the expression and the destinations of expressed RNAs in the cell. The human U1 snRNA is transcribed by RNA polymerase II and its expression is directed to the nucleus. In contrast, adenovirus VA1 RNA is transcribed by RNA polymerase III and its expression is directed to the cytoplasmatic compartment. The subcellular localization of the chimeric U1 -and VA1 -ribozyme transcripts was ascertained by FISH experiments using a DIG -labeled ribozyme RNA probe. As shown in Figure 2 , the chimeric U1 -RibB3A2 transcript was localized almost exclusively in the nucleus (Fig 2C ) , whereas the chimeric VA1 -RibB3A2 RNA showed a prominent cytoplasmatic localization ( Fig 2E ) .
Transduction of murine 32D -LG7 myeloid cells
The efficacy of the recombinant retroviral vectors expressing the anti -bcr-abl ribozymes was assessed by transduction of 32D -LG7 cells, a derivative of the 32D myeloblast cell line obtained by transduction of the bcrabl cDNA. 29 Parental 32D cells display an IL -3 -dependent growth phenotype and, in the absence of this cytokine, they rapidly die by apoptosis. By contrast, high -level expression of the p210 bcr -abl protein renders 32D -LG7 cells no longer dependent on the addition of IL -3. 41 It is predictable that the reduction of the levels of expression of p210 bcr -abl would determine the restoration of IL-3 dependency and the consequent impairment of cell viability in the absence of the cytokine. Given this property, this cell line represents a convenient model for the analysis of the efficiency of antibcr-abl therapeutic agents.
32D -LG7 cells were transduced with the two recombinant retroviral vectors in the presence of IL -3 and were maintained in the presence of the cytokine for additional 48 hours after transduction to allow recovery from any possible toxic effect of the transduction procedure itself on cell viability. After this period, cells were split in two cultures and grown either with or without IL -3 for additional 15 days. As controls we produced three additional retroviral vectors, transducing the N2A vector backbone, the N2A vector with the VA1 cloning cassette in the LTR, and the VA1 cassette with a ribozyme in which the catalytic site bears an inactivating point mutation. These constructs represent controls for possible effects of transduction, VA1 expression or antisense activity, respectively.
The proliferation kinetics of 32D -LG7 cells that were mock transduced with the retroviral vectors expressing the ribozymes and the controls are shown in Figure 3A -C. Cells that were mock transduced or transduced with vector alone or vector expressing VA1 showed no differences in their proliferation either in the presence or absence of IL-3. Similarly, cells transduced with U1 -RibB3A2 or VA1 -RibB3A2 proliferated at unaltered growth rate when maintained in IL -3 medium. By contrast, for both retroviral transductions, removal of IL -3 resulted in a rapid impairment in cell growth occurring in the first few days after gene transfer. This loss of cellular proliferation was more evident in the cell culture transduced with the VA1 -RibB3A2 vector ( Fig 3C ) . After the first $5 days, proliferation rates returned identical for all the cultures, as it appears from the comparable curve slopes. Interestingly, the effect observed with the VA1 -ribozyme construct was abolished when the mutated version of the ribozyme was tested (Fig 3C ) .
The sharp decrease in cell proliferation that was observed in the cell cultures treated with the U1 -and the VA1 -ribozymes when cultured without IL -3 prompted us to verify the possibility that the two vectors were responsible for the induction of apoptosis in the transduced cells in the absence of the cytokine. This analysis was performed by the cytofluorimetric evaluation of the proportion of cells expressing phosphatidylserine residues on the cell membrane reacting to fluorescein -labeled annexin V. 42 The analysis performed in cells transduced with the VA1 -RibB3A2 retrovirus is shown in Figure 4 . In transduced cells cultured in the absence of IL -3, a remarkable proportion of cells underwent apoptosis at few hours after transduction ( 30.8% and 85.1% at 24 and 50 hours after the end of the transduction procedure, respectively ). By contrast, mock -transduced cells cultured without IL-3 or transduced cells cultured with IL-3 showed a limited proportion of apoptotic cells at time 0 after transduction ( <20%, most likely due to the transduction procedure itself ), which returned to background levels ( < 10% ) at 50 hours after transduction.
Altogether, these observations indicate that transduction of 32D -LG7 cells with the retroviral vectors expressing the VA1 -RibB3A2 ribozyme and, to a lesser extent, the U1 -RibB3A2 ribozyme determines a marked impairment in cell proliferation by committing the cells to programmed cell death.
Molecular events induced by ribozyme expression
Induction of apoptosis by the vectors expressing the RibB3A2 ribozymes is consistent with the reduction in the cellular proliferation rate observed at few days after trans-
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Targeted anti-bcr-abl ribozymes Mendoza -Maldonado et al duction, which is shown in Figure 3 . Still, cell growth resumed after day 5 at a pace similar to mock -transduced cells. Therefore, we set out to understand which were the molecular events underlying these observations and developed a quantitative procedure for the precise quantification of the number of transduced cells and of the levels of bcr-abl transcript, based on competitive PCR. Primers were selected for the amplification of the proviral DNAs and transcripts containing the U1 -RibB3A2 and VA1 -RibB3A2 cassettes and for the b3a2 translocation mRNA. Amplification was also carried out for the -globin gene ( for DNA samples ) and for the -actin mRNA ( for RNA samples ), to obtain standardization of the total analyzed quantities of DNA and RNA. For each of the examined regions, competitors were constructed that correspond to the investigated sequences but differ in size. 33 -35 A schematic representation of the localization of the primer pairs used in this work is shown in Figure 5 , along with an example of competitive PCR amplification for each of the investigated regions. Figure 6 Quantification of bcr -abl mRNA in transduced cells. The histograms show the ratio between the bcr -abl and the -actin mRNA, as evaluated by competitive PCR at different times after transduction, in 32D -LG7 cells that were mock transduced or transduced with the N2A vector expressing empty VA1 -for day 5 only -( A ), cells transduced with the retroviral vectors expressing the U1 -RibB3A2 ( B ), and cells transduced with the VA1 -RibB3A2 or VA1 -RibB3A2m ribozymes -the latter at day 5 only ( C ). After transduction, cells were kept either in the presence or absence of IL -3, as indicated. Each histogram corresponds to the mean of at least three independent experiments, with the indication of the standard deviation. Figure 7 Detection of p210 bcr -abl protein in transduced cells. The p210
bcr -abl and normal Abl protein levels were analyzed by Western blotting in 32D cells and in 32D -LG7 cells at different times after transduction with the retroviral vectors expressing the anti -bcr -abl ribozymes. A: End of the transduction procedure ( performed in the presence of IL -3 ). Lanes 1 and 3 are mock -transduced 32D -LG7 cells grown in the absence or presence of IL -3, respectively. B: Day 2 after transduction. The p210 bcr -abl protein is markedly decreased in the transduced cells grown either in the presence ( lanes 8 and 10 ) or absence ( lanes 9 and 11 ) of IL -3. C: Day 5 after transduction. The levels of p210 bcr -abl in the transduced cell populations are less reduced than at day 2 ( lanes 15 -18 ), according to the progressive selection of untransduced cell populations ( see Fig 8 ) . Wild -type 32D cells grown in the presence of IL -3 are shown in lanes 2, 7, and 14.
The levels of bcr-abl mRNA remained unchanged after treatment in mock -transduced 32D -LG7 cells and in cells transduced with the vector expressing empty VA1 (Fig 6A ) . By contrast, cells transduced with either the U1 -RibB3A2 ( Fig 6B ) or the VA1 -RibB3A2 ( Fig 6C ) ribozymes showed an impressive reduction in the levels of this transcript, which was particularly evident at day 5 after transduction and for the VA1 -RibB3A2 construct. In all samples from transduced cells, the reduction of the bcr-abl mRNA levels was more pronounced in cells cultured in the presence of IL -3, in agreement with the selective pressure that ribozyme expression imposes on cells cultured in the absence of this cytokine. As far as the VA1 -ribozyme effect on bcr-abl mRNA is concerned, this has to be ascribed to the ribozyme catalytic activity itself, because the levels of bcr-abl were unaltered in cells transduced with the vector expressing the catalytically inactivated control (Fig 6C ) .
The results obtained by mRNA quantification were also confirmed by the analysis of the p210 bcr -abl protein by Western blotting. At day 2 after transduction, the levels of this protein were highly diminished in cells expressing the U1 -RibB3A2 ribozyme with respect to mock -transduced cells, and they were almost undetectable in cells expressing the VA1 -RibB3A2 ribozyme cultured either in the presence or absence of IL -3 ( Fig 7B ) . At day 5 after transduction, the levels of p210 bcr -abl were less reduced (Fig 7C ) , in agreement with the data on cellular proliferation and apoptosis indicating the progressive selection of untransduced cell populations.
We also analyzed the number of proviral DNA copies in cell cultures transduced with both vectors. In cultures maintained in the presence of IL -3, the ratio between proviral DNA and cellular -globin DNA remained almost unchanged during the first 15 days following the transduction procedure ( Fig 8) . By contrast, in cultures in which IL -3 was removed, a marked decrease in the number of provirus -containing cells was observed at day 5 after transduction ( $3 and $15 times for cultures transduced with the U1 -RibB3A2 ribozyme and the VA1 -RibB3A2 ribozyme vectors, respectively ). In both cultures, the number of provirus -containing cells only slightly decreased at subsequent time points, and was < 15% and < 5% for the U1 -and VA1 -RibB3A2 ribozymes, respectively, at day 15. The residual persistence of transduced cells in selective conditions might indicate transcriptional silencing of the U1 and VA1 cassettes over time.
Altogether, the above reported data indicate that the expression of the intracellular anti -bcr-abl ribozyme determines a strong reduction of levels of the p210 bcr -abl mRNA and protein. This reduction determines the return to an IL -3 -dependent phenotype, and confers a selective disadvantage to cells cultured under selective pressure, with consequent selective purging of transduced cells.
Transduction of Ph + cells from bone marrow of patients with CML
To extend these studies to clinically relevant target cell population, we next transduced primary CML Ph + progenitors cells. CML -bone marrow samples were extracted from three patients with a known B3A2 splice site ( patients CML -1, CML -10, and CML -11, see Fig 9 ) . The efficacy of the recombinant retroviral vector expressing the VA1 ribozyme was assessed by transduction of bone marrow Cancer Gene Therapy Quantitations of B3A2 mRNA, VA1 -B3A2 ribozyme, VA1 -B3A2 provirus, -actin RNA, and -globin gene were performed before and after infection by competitive PCR and RT-PCR. Transduction efficiency was 55%, 30%, and 100% in samples from patients CML -1, CML -10, and CML -11, respectively, as assessed from the ratio between provirus and endogenous -globin DNA copies at day 2 after transduction. The transduced cell populations were analyzed for B3A2 bcr-abl mRNA levels at days 2 and 5 after transduction. Figure 9 reports the results of these measurements, expressed as ratios to the respective cellular -actin mRNA levels. In all samples, a clear reduction was observed in the levels of the fusion transcript in transduced cultures, which was not apparent in mock -transduced cells. At day 5, this reduction was $5 -fold in patient CML -1, $10 -fold in patient CML -10 and over 1000 -fold in patient CML -11. Remarkably, the extent of suppression of B3A2 bcr-abl mRNA in the three samples was found to correlate with the levels of B3A2 -VA1 ribozyme that was expressed in the transduced cells. At day 2, these levels were 0.72, 1.1, and 18.8 ribozyme molecules per -actin mRNA molecules in patients CML -1, CML -10, and CML -11, respectively. Altogether, these results indicate that transduction of primary CML bone marrow cells with the retroviral vector expressing the B3A2 -VA1 ribozyme is effective in reducing the levels of the bcr-abl transcript, and suggest that efficacy is correlated to the levels of expression of the fusion ribozyme.
Discussion
One of the disorders that could benefit from the therapeutic expression of ribozymes is CML, as this disease is sustained by a defined genetic abnormality that is seminal to disease development. Because during the chronic phase of the disease malignant CD34 + hematopoietic precursors coexist with normal ones, the selective suppression of the former cell population by inhibiting bcr-abl expression is an attractive possibility for ex vivo purging attempts.
Several reports on the inhibition of bcr-abl expression in Ph + cell lines and primary CML cells by exogenous delivery of antisense nucleic acids or ribozymes directed to the bcrabl fusion sequences are available in the literature. In most cases, these investigations have only obtained a modest reduction in the levels of the bcr-abl mRNA and p210 bcr -abl protein, only in few cases associated with phenotypic changes. 14, 43 Contrary to the exogenous delivery of antisense or ribozyme molecules, their intracellular expression offers the possibility to obtain high concentration inside the cell for extended periods of time. In addition, expression of RNA therapeutics as fusions to cellular or viral RNAs confers stability and appropriate conformation and permits their targeting to specific subcellular compartments to colocalize with their targets, an essential requisite to attain therapeutic benefit. 22, 23 The results of this work indicate that an anti bcr-abl hammerhead ribozyme can be successfully expressed at high levels when cloned within the adenovirus VA1 RNA or the human U1 snRNA genes, and that, in both cases, the fusion transcripts maintain the same cellular localization as the correspondent wild -type RNAs.
To attain efficient intracellular delivery of both the U1 -and VA1 -ribozyme constructs, the respective transcriptional cassettes were cloned in the U3 region of a Moloney-based retroviral vector to obtain a double -copy vector. 44 In fact, studies conducted in the last years have shown that insertion of independent transcriptional units within the two viral LTRs in several instances results in silencing of ribozyme expression, possibly due to competition between the 5 0 LTR Figure 9 Suppression of B3A2 bcr -abl transcripts in primary CML bone marrow cells. Bone marrow mononuclear cells from three patients with CML with the B3A2 bcr -abl translocation were mock transduced ( mock ) or transduced with the retroviral vector expressing the VA1 -RibB3A2 ribozyme ( VA1 -Rib ), and analyzed for bcr -abl gene expression at 2 and 5 days after transduction. Shown are the levels of B3A2 mRNA expressed as a ratio to the -actin mRNA. All quantifications were performed by competitive RT -PCR. Each bar reports the mean and standard deviation of three independent quantification experiments.
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Targeted anti-bcr-abl ribozymes Mendoza -Maldonado et al and the inserted promoters. 39, 45, 46 By contrast, the anti -bcrabl ribozymes inserted in the U3 region were expressed in the target cells both as independent VA1 or U1 transcriptional units and as transcripts of proviral genomic length.
Hammerhead ribozymes fused to the U1snRNA have recently been described having as targets the Rev premRNA 47 and the Tat mRNAs 46 of HIV-1, the TAR RNA region of SIV, 46 the rat atrial natriuretic factor mRNA, 48 and the human fibrillin -1 mRNA. 49 The U1 gene is transcribed by RNA polymerase II but, in contrast to most mRNAs, it harbors a specialized termination signal and the resulting transcripts are not polyadenylated. 50 Similar to wild -type U1 snRNA, the RNA fusion obtained by the insertion of the anti -bcr-abl ribozyme immediately 5 0 of stem loop I was also predominantly nuclear, with a widely dispersed nucleoplasmic localization. 51 Accordingly, nuclear localization was also reported for a ribozyme -U1 construct containing the last 157 nt of the U1 snRNA sequence, 46 and for two replacement constructs in which the stem loop III 47 or the Sm binding site 49 of U1 were substituted with a ribozyme. Most likely, nuclear localization of U1 snRNA is determined by multiple redundant binding activities, some of which are still preserved in all these constructs. 49 Nuclear localization of ribozymes, however, is probably not best suited for the efficient cleavage of mature cellular or viral mRNAs. 46, 52 In this work, the intracellular expression of the anti-bcr-abl ribozyme fused to the cytoplasmically located VA1 RNA was far more powerful in the reduction of the target bcr-abl mRNA levels. The ribozyme was a substitute to a portion of the central domain of the adenovirus type 2 VA1 gene, 26 a region that does not influence transcription by RNA polymerase III or cellular localization of the RNA, whereas it mediates its inhibition of the cellular interferon -inducible kinase PKR. 53, 54 Sequence substitutions or deletions in this region prevent both binding to the kinase and inhibition of its activity. 54 -56 Ribozymes or antisense sequences cloned in this region are expressed at high levels inside the cells and maintain a specific cytoplasmic localization (see Ref. 26 and citations therein ). The anti -bcr-abl ribozyme inserted into VA1 was very effective in reducing the levels of the bcr-abl mRNA and p210 bcr -abl protein. The outcome of this reduction in the 32D -LG7 cell model was the induction of a potent apoptotic program. In the absence of any selection, and given the high efficiency of transduction obtained by these retroviruses, over 85% of the cells in the transduced cultures were induced to apoptose. It is unlikely that this is an unspecific effect due to inhibition of other cellular functions by the ribozyme, or to interference of VA1 with cellular functions, because this effect could be specifically reversed by the addition of IL -3. In addition, cell growth and bcr-abl mRNA levels were unchanged after transduction of VA1 alone or of VA1 containing an inactivated ribozyme sequence. Altogether these observations point to a specific effect of the active VA1 ribozyme in the restoration of an IL -3 -dependent phenotype similar to that of the parental 32D clone.
Inhibition of p210 bcr -abl expression and induction of apoptosis in 32D -LG7 cells by the VA1 ribozyme occurred in the absence of selective pressure, thus avoiding the use of any selectable gene in the vector construct. This consideration also applies to the pilot experiment performed by transduction of mononuclear cells from bone marrow samples of three patients with chronic phase CML. Similar to the results obtained by transduction of the CML cell line, also in this case transduction determined a marked reduction of B3A2 bcr-abl mRNA. This reduction was clearly correlated with the efficacy of expression of the VA1 ribozyme, being more pronounced in those samples where expression was higher. Although this preliminary experiment on primary cells is encouraging, its extension to a higher number of patients with different types of translocations and in different clinical phases of the disease is clearly needed before any definitive conclusion is drawn. It will also be interesting to understand whether the observed reduction in bcr-abl mRNA in the transduced cell population will eventually lead to the extinction of the proliferative capacity of these cells, an important requirement for a bone marrow purging approach. Finally, translation of these results to a clinically applicable protocol will also require that either 100% of progenitor cells are transduced with these retroviral vectors, or that those cells that are transduced are positively selected before transplantation.
More difficult to predict are the long -term effects of the fusion ribozymes on transduced normal cell populations and, in particular, whether they could interfere with the normal differentiation process. In this respect, preliminary observations obtained by transduction of a more extended series of CD34 + cells did not reveal any defect in proliferation or maturation of these cells in short -term cultures. In addition, a number of studies have already indicated that provirus gene expression in hematopoietic cells transduced with retroviral vectors is prone to progressive silencing, mediated by methylation and chromatin deacetylation at the sites of integration. 57, 58 To what extent this event, which would be desirable in this case, also occurs for polymerase II -and polymerase III -driven short RNAs still needs to be investigated.
